台灣民眾對大麻的觀感及大麻二酚使用者經驗：質與量的研究

Abstract

大麻二酚（CBD）為大麻素的一種，在台灣的規範屬於藥物，但因為大麻在台灣屬於二級毒品，對於大麻的態度可能會型塑CBD相關的政策。本研究試圖探討民眾對於大麻的觀感與對於大麻的認知知識否有落差，台灣CBD使用經驗的各面向探討對於使用者是否改善生活品質，衛生福利部食品藥物署CBD專藥申請管道與其他取得管道是否有差異性。本研究使用混合分析法，採用量化為主、質性為輔助補充。收集808份有效問卷，還有對於4位具有相關經驗的人進行訪談。問卷結果發現對於大麻的觀感較多認為是藥品，但對於大麻生理特性的認知與科學證據相較具有差異性。118位CBD使用經驗的受訪者自評生活品質有一定的改善程度。808位受訪者中約九成不熟悉專藥申請管道網頁。期望研究結果能為未來CBD相關政策做為參考。

Cannabidiol (CBD), a compound derived from cannabis, is categorized as a pharmaceutical substance in Taiwan due to the classification of cannabis as a Schedule II controlled drug. The public perception of cannabis may shape policies concerning CBD. This research aims to investigate whether there is a disparity between public perception and knowledge about cannabis and to explore various aspects of CBD usage in Taiwan, focusing on its improvement on users' quality of life. Additionally, we examine the differences between the Taiwan Food and Drug Administration's CBD import regulations on foods and related products for personal use and other acquisition channels. The study utilizes a mixed-methods approach, primarily employing quantitative analysis of 808 valid repondents in a public opionion survey, supplemented by qualitative interviews of four individuals with relevant experiences. The results revealed that the majority of respondents view cannabis as a medicinal substance, yet there were discrepancies in their understanding of its physiological properties and scientific evidence. Among the 118 respondents who reported CBD usage experiences, a considerable number perceived an improvement in their quality of life. Approximately 90% of the 808 respondents were unfamiliar with the CBD-specific pharmaceutical application process. We hope that the findings of this research will serve as a valuable reference for future CBD-related policy considerations.